The University of Florida has now begun Stage 2 in the process for reengaging on-campus research activities which have been interrupted by the COVID-19 pandemic.
The UF Office of Clinical Research has published guidance for resuming clinical research projects, which applies to all UF health-related human subjects research.
The University of Florida is beginning the process for reengaging on-campus research activities which have been interrupted by the COVID-19 pandemic.
UF Health Investigational Drug Services has developed a position statement on the issue of shipping dispensed Rx to research participants.
The UF Institutional Biosafety Committee has issued guidance regarding important biosafety rules and regulations pertaining to COVID-19.
Most of the UF workforce has transitioned to telework during the COVID-19 pandemic. UF|Research has created a webpage that offers suggestions for activities that advance research productivity while also keeping an active work status.
Investigators may need to alter protocols to minimize the spread of COVID-19. The following outlines if/when IRB needs to be notified.
We are seeking available supplies of N95 masks, gloves, long-sleeve Tyvek gowns, face shields, goggles, and other personal protective equipment (PPE) for UF Health clinician needs going into the COVID-19 epidemic.
COVID-19 is a significant challenge that will continue to impact our research on campus and across the state in the weeks ahead. Given the progression of impact on campus and across the state, please take the following actions immediately: Research activities that can be accomplished remotely should move to that…
The U.S. Food and Drug Administration has issued guidance for industry, investigators and institutional review boards conducting clinical trials during the coronavirus (COVID-19) pandemic. For more information, see https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-pandemic.